Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review.

Abstract

The increase in obesity and the aging of the population has lead to an increase in the incidence of type 2 diabetes. This has led to the development of new drugs such as thiazolidinediones (TZDs) which are Peroxisome Proliferator-Activated Receptor (PPARgamma) agonists, to treat type 2 diabetes. TZDs have recently been at the center of a controversy with regards to their cardiovascular safety. Pioglitazone is a TZD which has been shown to be effective in glycemic control by lowering insulin resistance. Pioglitazone also has beneficial effects on lipid metabolism and cardiovascular risk. The safety and efficacy of pioglitazone including its pleotropic effects are discussed at length in this article.

• Authors: Cyrus V Desouza, Vijay Shivaswamy
• Journal: Clinical medicine insights. Endocrinology and diabetes (Clin Med Insights Endocrinol Diabetes) Vol. 3 Pg. 43-51 ( 2010) ISSN: 1179-5514 [Print] United States
• PMID: 22879786 (Publication Type: Journal Article)